AbbVie Inc. (ABBV) vs Berkshire Hathaway Inc. (BRK-A)
See how AbbVie Inc. and Berkshire Hathaway Inc. differ across market data and performance, so you can decide which asset best fits your strategy.
$256.42
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
View Full Page$756,650
NYSE
Key Metrics Comparison
AbbVie Inc.ABBV
Market Cap$453.124B
Price$256.42
24h Change+0.37%
24h Volume$4.24M
Employees57,000
Shares Outstanding1,768,169,012
Berkshire Hathaway Inc.BRK-A
Market Cap$1.08T
Price$756,650
24h Change-0.18%
24h Volume$160
Employees387,800
Shares OutstandingN/A
Category Performance
Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.
Market Share
Share of combined market cap
ABBV
29.6%BRK-A
70.4%Volume Share
Share of combined 24h volume
ABBV
100.0%BRK-A
1.0%24h Performance
Price change over last 24 hours
ABBV
0.37%BRK-A
-0.18%Price Comparison
AbbVie Inc.
Berkshire Hathaway Inc.